The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.

@article{Bumer2010ThePL,
  title={The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.},
  author={W. B{\"a}umer and P. Wlaź and G. Jennings and C. Rundfeldt},
  journal={European journal of pharmacology},
  year={2010},
  volume={628 1-3},
  pages={
          226-32
        }
}
Miltefosine is currently marketed for treatment of skin metastasis of breast cancer and leishmaniasis. The mechanism of action is not fully understood, however, miltefosine is considered to be a prototype lipid raft modulator. The compound was shown to inhibit anti-IgE induced histamine release from human skin mast cells. After topical treatment it reduced skin reaction in allergic human volunteers undergoing a skin prick test. The aim of this study was to test whether miltefosine could also… Expand
29 Citations
Miltefosine Suppresses Inflammation in a Mouse Model of Inflammatory Bowel Disease
  • 8
Unique immunomodulatory effects of azelastine on dendritic cells in vitro
  • 4
  • PDF
Repurposing Miltefosine for the Treatment of Immune-Mediated Disease?
  • 8
  • PDF
Miltefosine: a novel treatment option for mast cell-mediated diseases
  • 11
The immunosuppressive characteristics of FB1 by inhibition of maturation and function of BMDCs
  • 5
Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
  • 10
  • PDF
...
1
2
3
...

References

SHOWING 1-10 OF 26 REFERENCES
A simple and effective method to assess murine delayed type hypersensitivity to proteins.
  • 89
Studies on toluene diisocyanate (TDI)-induced delayed type hypersensitivity.
  • 14
...
1
2
3
...